EDGAR Filing Documents for 0000950142-22-002222

Form 8-K - Current report:

SEC Accession No. 0000950142-22-002222

Filing Date

2022-07-15

Accepted

2022-07-15 17:03:23

Documents

Period of Report

2022-07-12

Items

Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Interactive Data

Document Format Files

Seq	Description	Document	Type	Size
1	FORM 8-K	eh220269223_8k.htm iXBRL	8-K	38224
2	EXHIBIT 99.1	eh220269223_ex9901.htm	EX-99.1	13970
	Complete submission text file	0000950142-22-002222.txt		279063

Data Files

Seq	Description	Document	Type	Size
3	XBRL SCHEMA FILE	nrxp-20220712.xsd	EX-101.SCH	3690
4	XBRL DEFINITION FILE	nrxp-20220712_def.xml	EX-101.DEF	26608
5	XBRL LABEL FILE	nrxp-20220712_lab.xml	EX-101.LAB	36687
6	XBRL PRESENTATION FILE	nrxp-20220712_pre.xml	EX-101.PRE	25232
8	EXTRACTED XBRL INSTANCE DOCUMENT	eh220269223_8k_htm.xml	XML	5562

Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801

Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134

NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)